GB2181435B - Recombinant lav/htlv virus and vaccines - Google Patents

Recombinant lav/htlv virus and vaccines

Info

Publication number
GB2181435B
GB2181435B GB8622987A GB8622987A GB2181435B GB 2181435 B GB2181435 B GB 2181435B GB 8622987 A GB8622987 A GB 8622987A GB 8622987 A GB8622987 A GB 8622987A GB 2181435 B GB2181435 B GB 2181435B
Authority
GB
United Kingdom
Prior art keywords
vaccines
htlv virus
lav
recombinant
recombinant lav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB8622987A
Other languages
English (en)
Other versions
GB8622987D0 (en
GB2181435A (en
Inventor
Shiu-Lok Hu
Anthony Frank Purchio
Linda Madisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of GB8622987D0 publication Critical patent/GB8622987D0/en
Publication of GB2181435A publication Critical patent/GB2181435A/en
Application granted granted Critical
Publication of GB2181435B publication Critical patent/GB2181435B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB8622987A 1985-09-25 1986-09-24 Recombinant lav/htlv virus and vaccines Expired - Fee Related GB2181435B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (3)

Publication Number Publication Date
GB8622987D0 GB8622987D0 (en) 1986-10-29
GB2181435A GB2181435A (en) 1987-04-23
GB2181435B true GB2181435B (en) 1990-01-10

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8622987A Expired - Fee Related GB2181435B (en) 1985-09-25 1986-09-24 Recombinant lav/htlv virus and vaccines

Country Status (22)

Country Link
CN (1) CN1020752C (enExample)
AT (1) ATA256786A (enExample)
CH (1) CH676247A5 (enExample)
DE (1) DE3690508T1 (enExample)
DK (1) DK455486A (enExample)
ES (2) ES2002490A6 (enExample)
FI (1) FI863848L (enExample)
FR (1) FR2587720A2 (enExample)
GB (1) GB2181435B (enExample)
GR (1) GR862412B (enExample)
HU (1) HU205780B (enExample)
IE (1) IE59314B1 (enExample)
IL (1) IL80073A (enExample)
IT (1) IT1195829B (enExample)
MY (1) MY103182A (enExample)
NL (1) NL8602422A (enExample)
NO (1) NO863803L (enExample)
NZ (1) NZ217645A (enExample)
PT (1) PT83434B (enExample)
SE (4) SE8604007L (enExample)
WO (1) WO1987002038A1 (enExample)
YU (1) YU46753B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109512T1 (de) * 1985-04-08 1994-08-15 Genetic Systems Corp Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ATE107861T1 (de) * 1986-09-19 1994-07-15 Oncogen Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
DE68917520T2 (de) * 1988-05-06 1995-01-05 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
EP0431128B1 (en) * 1989-06-01 2003-03-26 Applied Biotechnology, Inc. Vector coding for self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
WO1993009238A1 (en) * 1991-11-08 1993-05-13 The Upjohn Company Feline leukemia virus vaccines
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
CA2212682A1 (en) * 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ES2143570T3 (es) * 1995-09-06 2000-05-16 Schablonentechnik Kufstein Ag Procedimiento para la fabricacion de una plantilla de serigrafia.
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173529A1 (en) * 1984-08-22 1986-03-05 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Molecular clones of the genome of HTLV-III
EP0181150B1 (en) * 1984-10-31 1993-06-09 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (en) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
EP0387915B1 (en) * 1984-10-18 1993-03-10 Institut Pasteur F antigens of the human immunodeficiency virus, and their applications
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173529A1 (en) * 1984-08-22 1986-03-05 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Molecular clones of the genome of HTLV-III
EP0181150B1 (en) * 1984-10-31 1993-06-09 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
G.V.Quinnan"Vaccinia Vir *
Journal of Virology,Vol. *
Molecular and Cellular B *
Nature,Vol.312,pages 757 *
Nature,Vol.312,pages 760 *
Nature,Vol.320,pages 535 *
Nature,Vol.320,pages 537 *

Also Published As

Publication number Publication date
IE862525L (en) 1987-03-25
IL80073A0 (en) 1986-12-31
GB8622987D0 (en) 1986-10-29
CN1020752C (zh) 1993-05-19
NO863803D0 (no) 1986-09-24
HU205780B (en) 1992-06-29
SE9102975D0 (sv) 1991-10-14
FR2587720B2 (enExample) 1995-02-10
SE9102974D0 (sv) 1991-10-14
FR2587720A2 (fr) 1987-03-27
SE9102976L (sv) 1993-04-15
DK455486A (da) 1987-03-26
FI863848A0 (fi) 1986-09-24
IE59314B1 (en) 1994-02-09
ATA256786A (de) 1995-05-15
ES2002490A6 (es) 1988-08-16
MY103182A (en) 1993-05-29
YU165486A (en) 1989-08-31
SE9102975L (sv) 1993-04-15
ES2006941A6 (es) 1989-05-16
IT8667730A0 (it) 1986-09-24
NL8602422A (nl) 1987-04-16
SE8604007L (sv) 1987-03-26
DK455486D0 (da) 1986-09-24
IL80073A (en) 1995-01-24
HUT42133A (en) 1987-06-29
CH676247A5 (enExample) 1990-12-28
NZ217645A (en) 1991-11-26
YU46753B (sh) 1994-05-10
IT1195829B (it) 1988-10-27
WO1987002038A1 (en) 1987-04-09
SE9102976D0 (sv) 1991-10-14
GB2181435A (en) 1987-04-23
GR862412B (en) 1987-01-23
PT83434B (pt) 1988-07-29
FI863848A7 (fi) 1987-03-26
NO863803L (no) 1987-03-26
SE9102974L (sv) 1993-04-15
PT83434A (en) 1986-10-01
FI863848L (fi) 1987-03-26
DE3690508T1 (enExample) 1988-06-23
CN86106632A (zh) 1987-05-13
SE8604007D0 (sv) 1986-09-23

Similar Documents

Publication Publication Date Title
NZ217645A (en) Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
IL84270A0 (en) Nor-statine and nor-cyclostatine polypeptides
DK603888D0 (da) Rekombinant virus
DE3890874C5 (de) Rekombinante Viren
NZ220653A (en) Hiv env region peptides and d-retro versions thereof
GB8821528D0 (en) Recombinant vaccinia virus
DK412787A (da) Medicinsk-kirurgisk pose og dennes fremstilling
ZA881621B (en) Cyclic peptides and their preparation
IL83347A0 (en) Recombinant htlv-iii proteins and their use
EP0225777A3 (en) Insecticides and viruses
NZ224393A (en) Recombinant hiv envelope proteins and uses thereof
IL79880A0 (en) Recombinant virus
DE3760806D1 (en) Monohalogenotrifluorooxetane and its preparation
IL77496A0 (en) Anti-viral preparations comprising isatine-3-thiosemicarbazones
IL81920A0 (en) Vaccines and their preparation
GB2194235B (en) Dichlorotrifluoromethyltoluenes and preparation thereof
PT86162A (en) Recombinant protein expression
ZA878158B (en) Nor-statine and nor-cyclostatine polypeptides
EP0233740A3 (en) Aerocavin and aerocyanidin - antibiotics
GB8608991D0 (en) Virus vaccine
GR3003377T3 (en) Virus vaccine
GB8406901D0 (en) Virus vaccine
BG39532A1 (en) Thermoresistant and chemicoresistant ceramic mass
IE852241L (en) Peptides and vaccines against malaria
DK125786D0 (da) Peptider og fremstilling deraf

Legal Events

Date Code Title Description
711B Application made for correction of error (sect. 117/77)
817A Application for correction of clerical errors now open to opposition (sect. 117/1977)
711B Application made for correction of error (sect. 117/77)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19960924